Our Pricing

Best Price For Wegovy UK With Discount Code WEIGHTLOSSNEW

Published on: June 03, 2026

Finding the best price for Wegovy UK means comparing registered pharmacies that offer transparent pricing and genuine UK-licensed medication. At Cured Pharmacy, Wegovy starts from £79.00 with discount code WEIGHTLOSSNEW, including a free clinical consultation with UK prescribers and discreet next-day delivery across the United Kingdom.

How Wegovy Semaglutide Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities [1]. Semaglutide mimics the natural GLP-1 hormone, which regulates appetite by acting on areas of the brain that control hunger and food intake.

In the landmark STEP 1 trial involving 1,961 adults, participants using Wegovy achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. This represents one of the most significant weight loss outcomes observed in clinical trials for pharmacological obesity treatment. Wegovy also demonstrated improvements in cardiovascular risk factors, including reductions in waist circumference, blood pressure, and HbA1c levels in those with prediabetes [2].

The medication works by slowing gastric emptying, reducing appetite, and increasing feelings of fullness after meals. Clinical response typically becomes evident within the first 12-16 weeks of treatment, with maximum effects observed after dose escalation to the maintenance dose of 2.4 mg weekly [1]. All patients require ongoing lifestyle modifications including a reduced-calorie diet and increased physical activity for optimal results.

Best Price for Wegovy UK: What You're Actually Paying For

When comparing the best price for Wegovy UK across registered pharmacies, it's essential to understand what's included in the total cost. At Cured Pharmacy, the £79.00 starting price covers the medication itself, a comprehensive clinical assessment by a UK-registered prescriber, and discreet delivery to your door. There are no hidden consultation fees or subscription traps—prices are transparent and shown upfront before you complete your medical questionnaire.

Wegovy is supplied as pre-filled, single-use injection pens in a dose-escalation schedule. Treatment begins at 0.25 mg weekly for four weeks, gradually increasing every four weeks until reaching the maintenance dose of 2.4 mg [3]. This titration schedule minimises gastrointestinal side effects and improves treatment tolerability. Your prescriber will determine the appropriate dose progression based on your clinical response and tolerance.

Superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all prescriptions dispensed from Cured Pharmacy, ensuring every patient receives genuine UK-licensed medication that meets MHRA standards. Our clinical team reviews each consultation individually, and medication is only dispensed following prescriber approval. This rigorous process protects patient safety whilst maintaining competitive pricing.

Understanding Wegovy Discount Codes

The discount code WEIGHTLOSSNEW provides £79.00 off your first Wegovy prescription at Cured Pharmacy, reducing the starting price and making treatment more accessible. This discount applies automatically during checkout when you enter the code, with no minimum purchase requirements or subscription commitments. Unlike promotional codes that expire after limited-time offers, WEIGHTLOSSNEW remains available to new patients seeking cost-effective weight management solutions through our pharmacy.

Wegovy vs Other Weight Loss Injections Available in the UK

The UK market now offers several GLP-1 receptor agonist injections for weight management, each with distinct mechanisms and clinical profiles. Understanding these differences helps patients and prescribers select the most appropriate treatment based on individual circumstances, tolerance, and weight loss goals.

Wegovy (semaglutide) and Saxenda (liraglutide) are both single-pathway GLP-1 agonists, but differ significantly in dosing frequency and efficacy. Wegovy requires once-weekly injections, whilst Saxenda necessitates daily administration. In head-to-head comparisons, semaglutide demonstrated superior weight loss outcomes—participants lost approximately 5-6% more body weight with semaglutide compared to liraglutide over comparable treatment periods [2][4].

Newer dual-pathway medications like Mounjaro (tirzepatide) activate both GIP and GLP-1 receptors, potentially offering enhanced weight loss compared to single-pathway treatments. However, Wegovy remains the most extensively studied GLP-1 medication for weight management in the UK, with robust long-term safety data and proven cardiovascular benefits [2]. Your prescriber will assess your medical history, contraindications, and treatment preferences to recommend the most suitable option.

Who Can Use Wegovy?

Wegovy is licensed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [3]. The medication is contraindicated in patients with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease. Pregnant or breastfeeding women should not use Wegovy, and treatment should be discontinued at least two months before planned conception.

How to Use Wegovy Injection Pens Safely

Wegovy arrives as pre-filled, single-use pens that require subcutaneous injection once weekly, on the same day each week. Patients can self-administer injections into the abdomen, thigh, or upper arm, rotating injection sites to reduce the risk of lipodystrophy. Each pen is designed for single use only and should be disposed of in a sharps container after administration.

Before your first injection, your prescriber or pharmacist will provide detailed instructions on proper injection technique. The pen does not require manual needle attachment—simply remove the cap, place the pen against your skin at a 90-degree angle, and press the dose button until you hear a click. Hold the pen in place for at least six seconds to ensure complete dose delivery [3]. Store unused pens in the refrigerator between 2°C and 8°C, and never freeze the medication.

Common side effects include nausea, diarrhoea, vomiting, constipation, and abdominal pain, particularly during the dose-escalation phase [1][3]. These effects typically diminish as your body adjusts to the medication. If you experience persistent vomiting, severe abdominal pain, or signs of pancreatitis, contact your prescriber immediately. Wegovy can slow gastric emptying, which may affect the absorption of oral medications—discuss timing with your healthcare provider if you take other prescription medicines.

Clinical Evidence: STEP Trial Programme Results

The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial programme represents the most comprehensive investigation of semaglutide for weight management, involving over 4,500 participants across five major trials. These studies established the efficacy and safety profile that led to Wegovy's MHRA approval in the UK.

STEP 1, the pivotal trial, demonstrated that 86.4% of participants on Wegovy 2.4 mg achieved at least 5% weight loss, compared to 31.5% on placebo [1]. More impressively, 50.5% of Wegovy participants lost 15% or more of their initial body weight—a threshold associated with significant improvements in obesity-related comorbidities. These results were sustained throughout the 68-week treatment period, with participants maintaining weight loss as long as they continued medication [1].

STEP 2 specifically examined semaglutide in patients with type 2 diabetes, showing an average weight reduction of 9.6% alongside improvements in glycaemic control [2]. STEP 5 extended follow-up to 104 weeks, confirming that weight loss persists with continued treatment and that cardiovascular risk markers continue to improve over time [4]. The consistent results across diverse patient populations demonstrate Wegovy's effectiveness in real-world clinical scenarios, subject to individual response and adherence to lifestyle modifications.

Long-Term Safety Considerations

Long-term safety data from the STEP trials and post-marketing surveillance indicate that Wegovy is generally well-tolerated when prescribed appropriately [1][2][4]. The most common adverse events are gastrointestinal in nature and typically resolve within the first few months of treatment. Rare but serious risks include pancreatitis, gallbladder disease, and potential thyroid C-cell tumours observed in rodent studies—though no causal relationship has been established in humans. Regular monitoring by your prescriber ensures early detection of any concerning symptoms.

Starting Your Wegovy Treatment at Cured Pharmacy

Beginning Wegovy treatment at Cured Pharmacy starts with a free online consultation that takes under three minutes to complete. You'll answer questions about your medical history, current medications, weight loss goals, and any contraindications. Our UK-registered clinical team reviews every submission individually—there are no automated approvals. If Wegovy is deemed appropriate for you, a prescription is issued and your medication is dispensed from our GPhC-registered pharmacy (registration number 9012511).

Your first prescription will typically include the initial dose-escalation pens, starting at 0.25 mg for the first month. Clear instructions accompany every delivery, along with information on proper storage, injection technique, and what to expect during treatment. Cured Pharmacy provides 100% discreet packaging with no external branding, and delivery is completed via next-day courier across the UK. You'll receive tracking information once your order is dispatched.

Ongoing treatment requires regular clinical review to assess response, tolerability, and appropriateness of dose escalation. NICE guidance recommends discontinuing treatment if patients do not achieve at least 5% weight loss after 12 weeks at the maintenance dose [3]. Your prescriber will monitor your progress and adjust treatment accordingly. For questions about your prescription or clinical concerns during treatment, contact our pharmacy team on (+44) 116 4646009 or consult your GP for in-person assessment if needed.

Reordering and Repeat Prescriptions

Once you've completed your initial consultation and started treatment, reordering Wegovy is straightforward through your Cured Pharmacy account. Repeat prescriptions still require clinical review to ensure ongoing suitability, but the process is streamlined for existing patients. Set reminders for your next order to avoid treatment interruptions, as consistency is essential for maintaining weight loss results. The discount code WEIGHTLOSSNEW applies to first orders only, but our everyday pricing remains the most competitive in the UK market.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Davies, M., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
3. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Retrieved from https://www.medicines.org.uk/emc/product/13799/smpc [accessed 13 August 2026]
4. Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is indicated for weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with weight-related comorbidities, alongside a reduced-calorie diet and increased physical activity. Individual results may vary. Do not use Wegovy if you have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Common side effects include nausea, diarrhoea, and gastrointestinal discomfort. Contact your prescriber if you experience severe or persistent symptoms.